Compound · clinical trials

Opdivo clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 152 trials in our USA, Canada, Spain, Australia, Israel, Mexico, France, Germany, Italy, UK, Netherlands, Poland, China, South Korea, Taiwan, Brazil, Belgium, Czechia, Japan, Norway, Denmark, Egypt, Turkey, Singapore, Austria, Switzerland, Sweden, Portugal, Ireland and India registers that name Opdivo as an intervention. Synced 10 Nov 2026

152Current trials

61Recruiting now

78Lead sponsors

30Country registers

Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Synced 10 Nov 2026 · Editorial standards

At a glance

Opdivo is named as an intervention in 152 current clinical trials in our USA, Canada, Spain, Australia, Israel, Mexico, France, Germany, Italy, UK, Netherlands, Poland, China, South Korea, Taiwan, Brazil, Belgium, Czechia, Japan, Norway, Denmark, Egypt, Turkey, Singapore, Austria, Switzerland, Sweden, Portugal, Ireland and India registers. 61 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is National Cancer Institute (NCI) (35). The most-studied condition is Melanoma.

Patient leaflets for Opdivo

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

UK
United Kingdom: Search MHRA Products
Patient information leaflets and SmPCs for UK-licensed products.
US
United States: Search DailyMed
FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Trials by status

Recruiting6140%
Not yet open43%
Active, closed8657%
By invitation11%

Trials by phase

Phase 27549%
Phase 33422%
Phase 11711%
Phase 1/21611%
Phase 2/364%
Phase 421%
Not applicable21%

Clinical trials of Opdivo

152 trials

Study	Phase	Status	Lead sponsor	Registers
The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials NCT05203172 · Solid Tumors	Phase 4	Recruiting	Pfizer	UK, USA, Germany, France, Spain, Italy, Netherlands, Czechia, Portugal, Turkey, Canada, Brazil, South Korea, Australia, Israel
Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma NCT06934057 · ClinicalTrials.gov ↗ · Kidney Cancer, Renal Cell Cancer	Phase 4	Recruiting	Gustave Roussy, Cancer Campus, Grand Paris	France
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab NCT05675410 · ClinicalTrials.gov ↗ · Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8	Phase 3	Recruiting	National Cancer Institute (NCI)	Canada, Mexico, Israel, Egypt
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma NCT05677490 · ClinicalTrials.gov ↗ · Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma	Phase 3	Recruiting	Alliance for Clinical Trials in Oncology	Mexico
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) NCT06112314 · Advanced Melanoma	Phase 3	Recruiting	Immunocore Ltd	UK, USA, Germany, France, Spain, Italy, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Mexico, Australia
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3] NCT06264180 · Advanced Melanoma	Phase 3	Recruiting	Replimune, Inc	UK, USA, Germany, France, Spain, Poland
CARE1 Pragmatic Clinical Trial NCT06364631 · Metastatic Kidney Cancer, Metastatic Kidney Carcinoma	Phase 3	Recruiting	Gustave Roussy, Cancer Campus, Grand Paris	France, Netherlands, Austria, Czechia
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma NCT06743126 · Melanoma, Cutaneous Malignant, Mucosal Melanoma	Phase 3	Recruiting	Immatics US, Inc	UK, USA, Germany, France, Netherlands, Canada, Israel
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial NCT07166406 · ClinicalTrials.gov ↗ · Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8	Phase 3	Recruiting	NRG Oncology	Canada, Mexico
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC) NCT07541170 · Non-small Cell Lung Cancer	Phase 3	Recruiting	Hoffmann-La Roche	Ireland, UK, USA, China, Germany, Spain, Italy, Poland, Portugal, Canada, Brazil, Japan, South Korea
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC NCT07720284 · High-risk Muscle Invasive Urothelial Carcinoma	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China, Germany, France, Spain, Italy, Poland, Canada, Brazil, Japan, South Korea, Taiwan, Australia
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study NCT05987241 · ClinicalTrials.gov ↗ · Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma, Muscle Invasive Ureter Urothelial Carcinoma	Phase 2/3	Recruiting	National Cancer Institute (NCI)	Canada, Mexico, Israel
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial NCT06203600 · ClinicalTrials.gov ↗ · Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma	Phase 2/3	Recruiting	National Cancer Institute (NCI)	Mexico
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma NCT06581406 · Metastatic Uveal Melanoma	Phase 2/3	Recruiting	Replimune, Inc	UK, USA, Australia
The Drug Rediscovery Protocol (DRUP Trial) NCT02925234 · ClinicalTrials.gov ↗ · Cancer, Tumors, Neoplasm	Phase 2	Recruiting	The Netherlands Cancer Institute	Netherlands
Combination of TATE and PD-1 Inhibitor in Liver Cancer NCT03259867 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Gastric Cancer	Phase 2	Recruiting	Teclison Ltd	USA
Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study) NCT03340129 · ClinicalTrials.gov ↗ · Melanoma Stage Iv	Phase 2	Recruiting	Melanoma Institute Australia	Norway, Australia
Melanoma Metastasized to the Brain and Steroids NCT03563729 · ClinicalTrials.gov ↗ · Malignant Melanoma	Phase 2	Recruiting	Inge Marie Svane	Denmark
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors NCT03866382 · ClinicalTrials.gov ↗ · Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma, Bladder Mixed Adenocarcinoma	Phase 2	Recruiting	National Cancer Institute (NCI)	Israel
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) NCT04546399 · ClinicalTrials.gov ↗ · Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia	Phase 2	Recruiting	National Cancer Institute (NCI)	Canada, Australia, Israel
Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based Treatment NCT04875611 · ClinicalTrials.gov ↗ · Nasopharyngeal Cancer	Phase 2	Recruiting	Maria Sklodowska-Curie National Research Institute of Oncology	Poland
Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC NCT04912765 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Hepatocellular Cancer, Colorectal Cancer	Phase 2	Recruiting	National Cancer Centre, Singapore	Singapore
Using ctDNA to Determine Therapies for Lung Cancer NCT04966663 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer, Complete Surgical Resection, Circulating Tumor DNA	Phase 2	Recruiting	University Health Network, Toronto	Canada
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma NCT05112601 · ClinicalTrials.gov ↗ · Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma	Phase 2	Recruiting	National Cancer Institute (NCI)	Mexico
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study NCT05136196 · ClinicalTrials.gov ↗ · Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8	Phase 2	Recruiting	National Cancer Institute (NCI)	Mexico
CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma NCT05257590 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Advanced Cancer	Phase 2	Recruiting	TaiRx, Inc	Taiwan
Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC NCT05310643 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer	Phase 2	Recruiting	GERCOR - Multidisciplinary Oncology Cooperative Group	France
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial NCT05327686 · Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8	Phase 2	Recruiting	NRG Oncology	Ireland, Canada, Mexico, Australia, Israel
Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer NCT05492123 · ClinicalTrials.gov ↗ · Uterine Cervical Neoplasms	Phase 2	Recruiting	Hospital Israelita Albert Einstein	Brazil
Immunotherapy in Patients With Early dMMR Rectal Cancer NCT05732389 · ClinicalTrials.gov ↗ · Cancer of Rectum	Phase 2	Recruiting	Odense University Hospital	Denmark
Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC) NCT05795244 · ClinicalTrials.gov ↗ · Endometrial Neoplasms, Endometrial Cancer	Phase 2	Recruiting	Yonsei University	South Korea
Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases NCT05909618 · ClinicalTrials.gov ↗ · Advanced Glioblastoma, Metastatic Melanoma in the Central Nervous System, MGMT-Unmethylated Glioblastoma	Phase 2	Recruiting	Sheba Medical Center	Israel
Nivolumab Combined With Chemotherapy in the Treatment of Primary Tracheal Squamous Cell Carcinoma NCT05964101 · ClinicalTrials.gov ↗ · Neoplasms, Carcinoma, Squamous, Antineoplastic Agents	Phase 2	Recruiting	The First Affiliated Hospital of Guangzhou Medical University	China
Nivolumab in Children and Adults With Nasopharyngeal Carcinoma NCT06019130 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma, Nasopharyngeal Cancer, Nasopharyngeal Neoplasms	Phase 2	Recruiting	German Society for Pediatric Oncology and Hematology GPOH gGmbH	Germany
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer NCT06029270 · ClinicalTrials.gov ↗ · Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8	Phase 2	Recruiting	National Cancer Institute (NCI)	Canada, Singapore, Australia
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma NCT06053658 · ClinicalTrials.gov ↗ · Renal Cell Carcinoma	Phase 2	Recruiting	M.D. Anderson Cancer Center	Israel
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) NCT06064097 · ClinicalTrials.gov ↗ · Stage II Nasopharyngeal Carcinoma AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8	Phase 2	Recruiting	National Cancer Institute (NCI)	Canada, Australia, Israel
First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer NCT06253611 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 2	Recruiting	GERCOR - Multidisciplinary Oncology Cooperative Group	France
Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC NCT06554613 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 2	Recruiting	Second Affiliated Hospital of Nanchang University	China
ONO-4538 Study in Patients With Richter's Transformation NCT06936943 · ClinicalTrials.gov ↗ · Richter's Transformation	Phase 2	Recruiting	Ono Pharmaceutical Co., Ltd	Japan
A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer NCT06948448 · Colorectal Cancer	Phase 2	Recruiting	Ono Pharmaceutical Co., Ltd	USA, France, Spain, Italy, Canada, Japan
Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure NCT07219459 · Unresectable or Metastatic Hepatocellular Carcinoma, Child-Pugh A Hepatocellular Carcinoma, Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound	Phase 2	Recruiting	CatalYm GmbH	UK, USA, Germany, France, Spain, Italy
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC NCT07246863 · ClinicalTrials.gov ↗ · Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor	Phase 2	Recruiting	CatalYm GmbH	USA, Germany, Spain, Italy, Poland, Switzerland
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors NCT02813135 · ClinicalTrials.gov ↗ · Pediatric Cancer	Phase 1/2	Recruiting	Gustave Roussy, Cancer Campus, Grand Paris	France, Spain, Italy, Netherlands, Denmark
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors NCT03686124 · Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult	Phase 1/2	Recruiting	Immatics US, Inc	USA, Germany
INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies NCT03838042 · ClinicalTrials.gov ↗ · CNS Tumor, Solid Tumor	Phase 1/2	Recruiting	University Hospital Heidelberg	Germany, France, Netherlands, Sweden, Switzerland, Austria, Australia
Low Dose Nivolumab in Adults Living With HIV on Antiretroviral Therapy NCT05187429 · ClinicalTrials.gov ↗ · HIV I Infection	Phase 1/2	Recruiting	University of Melbourne	Singapore, Australia
A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors NCT05584670 · Solid Tumor	Phase 1/2	Recruiting	Sanofi	USA, Spain, Netherlands, Japan, Israel
FOG-001 in Locally Advanced or Metastatic Solid Tumors NCT05919264 · ClinicalTrials.gov ↗ · Cancer, Colorectal Cancer, Solid Tumor	Phase 1/2	Recruiting	Parabilis Medicines, Inc	USA, Australia
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis NCT06047379 · ClinicalTrials.gov ↗ · Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult	Phase 1/2	Recruiting	Neonc Technologies, Inc	USA
Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases NCT06163820 · ClinicalTrials.gov ↗ · Melanoma Brain Metastases	Phase 1/2	Recruiting	Melanoma and Skin Cancer Trials Limited	Australia
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy NCT06362369 · Advanced Cancer, Advanced Solid Tumor, Melanoma	Phase 1/2	Recruiting	7 Hills Pharma, LLC	USA
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors NCT06618287 · Lung Cancer, Breast Cancer	Phase 1/2	Recruiting	Bristol-Myers Squibb	UK, USA, France, Spain, Italy, Netherlands, Canada, Taiwan, Australia
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO NCT03816345 · ClinicalTrials.gov ↗ · Autoimmune Disease, Crohn Disease, Dermatomyositis	Phase 1	Recruiting	National Cancer Institute (NCI)	Canada
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors NCT05076760 · Solid Tumor, Advanced Cancer, Metastatic Cancer	Phase 1	Recruiting	Memgen, Inc	USA
Intrathecal Application of PD1 Antibody in Metastatic Solid Tumors With Leptomeningeal Disease (IT-PD1/ NOA 26) NCT05112549 · ClinicalTrials.gov ↗ · Leptomeningeal Disease	Phase 1	Recruiting	University Hospital Tuebingen	Germany
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors NCT05176483 · Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC)	Phase 1	Recruiting	Exelixis	UK, USA, Germany, France, Spain, Italy, Belgium, Poland, Switzerland, Austria, Australia, Israel
A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors NCT06764771 · Advanced Malignant Tumors	Phase 1	Recruiting	Bristol-Myers Squibb	USA, Canada, Australia
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma NCT07176650 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC)	Phase 1	Recruiting	Shanghai Henlius Biotech	USA, China
Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma NCT07476326 · ClinicalTrials.gov ↗ · Melanoma	Phase 1	Recruiting	Biocon Biologics UK PLC	Spain, Turkey, Brazil
A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors NCT07518043 · ClinicalTrials.gov ↗ · Esophageal and/or Cardia Cancer, Melanoma, Urothelial Carcinoma (UC)	Phase 1	Recruiting	Shanghai Henlius Biotech	China
iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma NCT07815574 · Melanoma (Skin Cancer), Advanced Melanoma, Metastatic Melanoma	Phase 3	Not yet open	Scancell Ltd	UK, USA
An Exploratory Study of Single-Dose Neoadjuvant Nivolumab Without Surgical Delay in Patients With Resectable HCC NCT07902258 · ClinicalTrials.gov ↗ · Hepato Cellular Carcinoma (HCC), Immune Checkpoint Inhibitor, Neoadjuvant Therapy	Phase 2	Not yet open	National Taiwan University Hospital	Taiwan
NIVO+IPI Neoadjuvant Therapy for Recurrent Resectable HCC NCT07919717 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC), Recurrent Hepatocellular Cancer	Phase 2	Not yet open	Shanghai Zhongshan Hospital	China
A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC) NCT07848295 · Clear Cell Renal Cell Carcinoma (ccRCC)	Phase 1	Not yet open	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company	USA, Germany, France, Spain, Italy, Netherlands, Belgium
Intraperitoneal Immune Checkpoint Inhibitor for Malignant Ascites NCT05745233 · ClinicalTrials.gov ↗ · Malignant Ascites	Not applicable	By invitation	China Medical University Hospital	China, Taiwan
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma NCT02224781 · ClinicalTrials.gov ↗ · Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Mexico, Egypt
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial) NCT02595944 · ClinicalTrials.gov ↗ · Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7	Phase 3	Active, closed	National Cancer Institute (NCI)	Mexico, Israel
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers NCT02785952 · Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7	Phase 3	Active, closed	SWOG Cancer Research Network	Canada, Mexico, Israel
Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy NCT03055013 · ClinicalTrials.gov ↗ · Metastatic Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v7	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Israel
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer NCT03233711 · ClinicalTrials.gov ↗ · Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Margin Squamous Cell Carcinoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Mexico, Israel, Egypt
A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation NCT03383458 · Hepatocellular Carcinoma, Liver Cancer	Phase 3	Active, closed	Bristol-Myers Squibb	UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Austria, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy NCT03522246 · Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer	Phase 3	Active, closed	pharmaand GmbH	Ireland, UK, USA, China, Germany, Spain, Italy, Belgium, Sweden, Denmark, Poland, Czechia, Turkey, Canada, Japan, South Korea, Taiwan, Singapore, Australia, Israel
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study NCT03793166 · ClinicalTrials.gov ↗ · Clear Cell Renal Cell Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes	Phase 3	Active, closed	National Cancer Institute (NCI)	Norway, Mexico
Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer NCT03811015 · ClinicalTrials.gov ↗ · Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8	Phase 3	Active, closed	National Cancer Institute (NCI)	Mexico, Egypt
A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer NCT03873402 · Renal Cell Carcinoma	Phase 3	Active, closed	Bristol-Myers Squibb	USA, France, Spain, Italy, Poland, Austria, Czechia, Portugal, Mexico
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma NCT03907488 · ClinicalTrials.gov ↗ · Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma, Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Mexico, Israel, Egypt
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma NCT03937219 · Renal Cell Carcinoma	Phase 3	Active, closed	Exelixis	UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Austria, Czechia, Canada, Brazil, Mexico, South Korea, Taiwan, Singapore, Australia, Israel
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer NCT04025879 · Carcinoma, Non-Small-Cell Lung	Phase 3	Active, closed	Bristol-Myers Squibb	Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Czechia, Canada, Brazil, Mexico, Japan, Taiwan, Australia
Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma NCT04099251 · Melanoma	Phase 3	Active, closed	Bristol-Myers Squibb	UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Czechia, Norway, Canada, Australia
Adjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk Melanoma NCT04309409 · ClinicalTrials.gov ↗ · Malignant Melanoma Stage II	Phase 3	Active, closed	University Hospital, Essen	Germany
New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy NCT04564157 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, Adjuvant Chemotherapy	Phase 3	Active, closed	Fundación GECP	Spain
Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma NCT04759586 · ClinicalTrials.gov ↗ · Primary Mediastinal Large B-Cell Lymphoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Australia
A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread NCT04810078 · Clear Cell Renal Cell Carcinoma	Phase 3	Active, closed	Bristol-Myers Squibb	Ireland, USA, France, Spain, Italy, Poland, Czechia, Portugal, Turkey, Brazil, Mexico
Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma NCT04949113 · ClinicalTrials.gov ↗ · Malignant Melanoma Stage III	Phase 3	Active, closed	The Netherlands Cancer Institute	Netherlands, Australia
A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer) NCT05144854 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 3	Active, closed	Ono Pharmaceutical Co., Ltd	China, Japan, South Korea, Taiwan
Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma NCT05678673 · Non-Clear Cell Renal Cell Carcinoma	Phase 3	Active, closed	Exelixis	UK, USA, Germany, France, Spain, Italy, Netherlands, Poland, Czechia, Turkey, Brazil, South Korea, Singapore, Australia
A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma NCT06022861 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 3	Active, closed	Shandong Boan Biotechnology Co., Ltd	China
A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma NCT06054555 · Melanoma	Phase 3	Active, closed	Amgen	USA, China, Germany, France, Spain, Italy, Netherlands, Czechia, Portugal, Turkey, Canada, Mexico, South Korea, Taiwan, Israel
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma NCT06097728 · Unresectable Pleural Mesothelioma	Phase 3	Active, closed	AstraZeneca	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Switzerland, Norway, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma NCT02339571 · Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7	Phase 2/3	Active, closed	National Cancer Institute (NCI)	Mexico, Israel
De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer NCT03952585 · Basaloid Squamous Cell Carcinoma, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8	Phase 2/3	Active, closed	National Cancer Institute (NCI)	Canada, Mexico
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma NCT05987332 · Metastatic Uveal Melanoma	Phase 2/3	Active, closed	IDEAYA Biosciences	UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Canada, Australia, Israel
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer NCT02257528 · ClinicalTrials.gov ↗ · Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Recurrent Cervical Carcinoma	Phase 2	Active, closed	National Cancer Institute (NCI)	Mexico
Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial NCT02275533 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Phase 2	Active, closed	National Cancer Institute (NCI)	Canada
Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer NCT02314169 · ClinicalTrials.gov ↗ · Anal Canal Squamous Cell Carcinoma, Metastatic Anal Canal Carcinoma, Stage IV Anal Cancer AJCC v8	Phase 2	Active, closed	National Cancer Institute (NCI)	Canada
Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases NCT02374242 · ClinicalTrials.gov ↗ · Melanoma, Brain Metastases	Phase 2	Active, closed	Melanoma Institute Australia	Australia
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) NCT02465060 · ClinicalTrials.gov ↗ · Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma	Phase 2	Active, closed	National Cancer Institute (NCI)	Norway, Mexico, Israel, Egypt
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors NCT02834013 · ClinicalTrials.gov ↗ · Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortical Carcinoma	Phase 2	Active, closed	National Cancer Institute (NCI)	Mexico, Egypt
A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib NCT02873962 · ClinicalTrials.gov ↗ · Peritoneal Cancer, Ovarian Cancer, Fallopian Tube Cancer	Phase 2	Active, closed	Dana-Farber Cancer Institute	Israel
Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma NCT03097939 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 2	Active, closed	National Cancer Centre, Singapore	Singapore
Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study) NCT03203473 · ClinicalTrials.gov ↗ · Renal Cancer	Phase 2	Active, closed	Toni Choueiri, MD	Israel
Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors NCT03333616 · ClinicalTrials.gov ↗ · Genitourinary Cancer, Adrenocortical Carcinoma, Non-urothelial Bladder	Phase 2	Active, closed	Dana-Farber Cancer Institute	Israel
Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer NCT03367741 · ClinicalTrials.gov ↗ · Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma, Recurrent Endometrial Carcinoma	Phase 2	Active, closed	National Cancer Institute (NCI)	Canada
A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC) NCT03595124 · ClinicalTrials.gov ↗ · Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8	Phase 2	Active, closed	National Cancer Institute (NCI)	Egypt
Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer NCT03637543 · ClinicalTrials.gov ↗ · Prostate Cancer	Phase 2	Active, closed	Beth Israel Deaconess Medical Center	Israel
Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2) NCT03703050 · ClinicalTrials.gov ↗ · Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma	Phase 2	Active, closed	Gustave Roussy, Cancer Campus, Grand Paris	France, Denmark
Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma NCT03712202 · ClinicalTrials.gov ↗ · Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage I Nodular Sclerosis Classic Hodgkin Lymphoma	Phase 2	Active, closed	City of Hope Medical Center	Israel
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) NCT03767348 · Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H), Non-melanoma Skin Cancer (NMSC)	Phase 2	Active, closed	Replimune, Inc	UK, USA, Germany, France, Spain
NADIM II: Neo-Adjuvant Immunotherapy NCT03838159 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer	Phase 2	Active, closed	Fundación GECP	Spain
Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206) NCT03865082 · Solid Tumor	Phase 2	Active, closed	Idera Pharmaceuticals, Inc	USA
Trial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer Patients NCT03921684 · Rectal Cancer	Phase 2	Active, closed	Baruch Brenner	Israel
Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma. NCT04006262 · ClinicalTrials.gov ↗ · Localized Oesogastric Adenocarcimona, MSI and or dMMR	Phase 2	Active, closed	GERCOR - Multidisciplinary Oncology Cooperative Group	France
Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors NCT04079712 · ClinicalTrials.gov ↗ · Metastatic Large Cell Neuroendocrine Carcinoma, Metastatic Neuroendocrine Carcinoma, Metastatic Neuroendocrine Neoplasm	Phase 2	Active, closed	National Cancer Institute (NCI)	Canada
Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM NCT04195139 · ClinicalTrials.gov ↗ · Glioblastoma Multiforme	Phase 2	Active, closed	University of Sydney	Australia
Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients. NCT04229459 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 2	Active, closed	Baruch Brenner	Israel
Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma NCT04300244 · ClinicalTrials.gov ↗ · Cancer, Cancer, Lung, Cancer of Lung	Phase 2	Active, closed	Åslaug Helland	Spain, Sweden, Denmark, Norway, Australia
Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer NCT04310007 · ClinicalTrials.gov ↗ · Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8	Phase 2	Active, closed	National Cancer Institute (NCI)	Mexico, Egypt
Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer NCT04361162 · ClinicalTrials.gov ↗ · Pancreatic Cancer, Metastatic Pancreatic Cancer	Phase 2	Active, closed	Massachusetts General Hospital	Israel
Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC NCT04413123 · ClinicalTrials.gov ↗ · Papillary Renal Cell Carcinoma, Unclassified Renal Cell Carcinoma, Translocation Renal Cell Carcinoma	Phase 2	Active, closed	Bradley A. McGregor, MD	Israel
Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial NCT04462406 · ClinicalTrials.gov ↗ · Advanced Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8	Phase 2	Active, closed	ECOG-ACRIN Cancer Research Group	Mexico
Nivolumab+Ipilimumab+RT in MSS mCRC NCT04575922 · ClinicalTrials.gov ↗ · Metastatic Microsatellite Stable Colorectal Cancer	Phase 2	Active, closed	Massachusetts General Hospital	Israel
Combination Immunotherapy in Rare Cancers Under InvesTigation NCT04969887 · Advanced Biliary Tract Cancer, Neuroendocrine Tumors, Female Reproductive System Neoplasm	Phase 2	Active, closed	Olivia Newton-John Cancer Research Institute	Australia
Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases NCT05012254 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer, Brain Metastases, Adult, Lung Cancer	Phase 2	Active, closed	Fundación GECP	Spain
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery NCT05111574 · ClinicalTrials.gov ↗ · Anal Melanoma, Bladder Melanoma, Cervical Melanoma	Phase 2	Active, closed	National Cancer Institute (NCI)	Canada
Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer NCT05148546 · ClinicalTrials.gov ↗ · Renal Cell Carcinoma	Phase 2	Active, closed	The Netherlands Cancer Institute	Netherlands
CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer Immunotherapy NCT05215470 · ClinicalTrials.gov ↗ · Renal Cancer Metastatic	Phase 2	Active, closed	Hospital das Clínicas de Ribeirão Preto	Brazil
Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation NCT05308446 · ClinicalTrials.gov ↗ · Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8	Phase 2	Active, closed	National Cancer Institute (NCI)	Egypt
Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer NCT05476796 · ClinicalTrials.gov ↗ · Gastric Adenocarcinoma, Esophagus Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma	Phase 2	Active, closed	UNICANCER	France
METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin NCT05504252 · ClinicalTrials.gov ↗ · Colorectal Adenocarcinoma, Mucinous Adenocarcinoma, Signet Ring Cell Adenocarcinoma	Phase 2	Active, closed	University Hospital, Akershus	Norway
DUMAS: Neo-Adjuvant Immunotherapy for Pancoast Tumors NCT05684276 · ClinicalTrials.gov ↗ · NSCLC, Pancoast Tumor	Phase 2	Active, closed	Fundación GECP	Spain
Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab. NCT05788081 · ClinicalTrials.gov ↗ · Follicular Lymphoma Stage II, Follicular Lymphoma Stage III, Follicular Lymphoma Stage IV	Phase 2	Active, closed	Olivia Newton-John Cancer Research Institute	Australia
Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma NCT05836571 · ClinicalTrials.gov ↗ · Locally Advanced Extraskeletal Myxoid Chondrosarcoma, Locally Advanced Leiomyosarcoma, Locally Advanced Liposarcoma	Phase 2	Active, closed	National Cancer Institute LAO	Canada
A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations NCT06101134 · Melanoma	Phase 2	Active, closed	Bristol-Myers Squibb	USA, Spain, Italy
Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab NCT06237920 · ClinicalTrials.gov ↗ · Urologic Neoplasms, Urogenital Neoplasms, Neoplasms by Site	Phase 2	Active, closed	The Netherlands Cancer Institute	Netherlands
A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer) NCT06256328 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 2	Active, closed	Ono Pharmaceutical Co., Ltd	China, Japan, South Korea, Taiwan
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC) NCT06534983 · Muscle-invasive Urothelial Carcinoma	Phase 2	Active, closed	Hoffmann-La Roche	UK, USA, Germany, Spain, Italy, Sweden, Denmark, Poland, Norway, Canada, South Korea, Taiwan, Australia
Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma NCT01896999 · ClinicalTrials.gov ↗ · Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma	Phase 1/2	Active, closed	National Cancer Institute (NCI)	Mexico
Safety and Feasibility of Irradiation and Nivolumab in Esophageal Cancer (INEC) NCT03544736 · ClinicalTrials.gov ↗ · Esophageal Cancer	Phase 1/2	Active, closed	Oslo University Hospital	Norway
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression NCT04180371 · Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer	Phase 1/2	Active, closed	BicycleTx Limited	UK, USA, Spain, Belgium, South Korea
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN NCT04317105 · ClinicalTrials.gov ↗ · Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm	Phase 1/2	Active, closed	National Cancer Institute (NCI)	Canada
A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors NCT04396821 · Advanced Cancer, Gastric Cancer, Gastroesophageal-junction Cancer	Phase 1/2	Active, closed	Transcenta Therapeutics (Hangzhou) Co., Ltd	USA
A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors NCT05888831 · Advanced Solid Tumors	Phase 1/2	Active, closed	Bristol-Myers Squibb	USA, France, Spain, Italy, Netherlands, Belgium
A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001) NCT02293980 · ClinicalTrials.gov ↗ · ccRCC, RCC, Kidney Cancer	Phase 1	Active, closed	Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	USA, Israel
Nivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3A NCT03245021 · ClinicalTrials.gov ↗ · Follicular Lymphoma	Phase 1	Active, closed	Dr. Eliza Hawkes	Australia
NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy NCT03589339 · Radiotherapy, Immunotherapy, Microsatellite Instability-High Solid Malignant Tumour	Phase 1	Active, closed	Nanobiotix	USA
Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer NCT03816358 · ClinicalTrials.gov ↗ · Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8	Phase 1	Active, closed	National Cancer Institute (NCI)	Canada
Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults NCT04323046 · ClinicalTrials.gov ↗ · Glioblastoma, Malignant Glioma, Recurrent Glioblastoma	Phase 1	Active, closed	Sabine Mueller, MD, PhD	Australia
Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors NCT04336241 · Cancer	Phase 1	Active, closed	Replimune, Inc	UK, Spain
Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy NCT05352828 · ClinicalTrials.gov ↗ · Classical Hodgkin Lymphoma, Hodgkin Disease Refractory, Hodgkin Disease Recurrent	Phase 1	Active, closed	Tessa Therapeutics	USA
A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors NCT06544655 · Advanced Solid Tumors	Phase 1	Active, closed	Bristol-Myers Squibb	USA, Canada, Australia
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) NCT02194738 · ClinicalTrials.gov ↗ · Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8	Not applicable	Active, closed	National Cancer Institute (NCI)	Norway, Mexico, Israel

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Conditions studied with Opdivo

286 conditions

Melanoma7 Solid Tumor6 Cancer5 Gastric Cancer5 Hepatocellular Carcinoma4Advanced Melanoma4Renal Cell Carcinoma4 Advanced Cancer4 Non Small Cell Lung Cancer4Metastatic Renal Cell Carcinoma3Clear Cell Renal Cell Carcinoma3 Colorectal Cancer3

All 286 conditions

Condition (as registered)	Trials
Melanoma	7
Solid Tumor	6
Cancer	5
Gastric Cancer	5
Hepatocellular Carcinoma	4
Advanced Melanoma	4
Renal Cell Carcinoma	4
Advanced Cancer	4
Non Small Cell Lung Cancer	4
Metastatic Renal Cell Carcinoma	3
Clear Cell Renal Cell Carcinoma	3
Colorectal Cancer	3
Clinical Stage III Cutaneous Melanoma AJCC v8	3
Clinical Stage IV Cutaneous Melanoma AJCC v8	3
Fallopian Tube Cancer	2
Stage III Renal Cell Cancer AJCC v8	2
Stage IV Renal Cell Cancer AJCC v8	2
Non-small Cell Lung Cancer	2
Lung Cancer	2
Ovarian Cancer	2
Metastatic Melanoma	2
Metastatic Uveal Melanoma	2
Urothelial Carcinoma (UC)	2
Kidney Cancer	2
Advanced Solid Tumors	2
Brain Metastases, Adult	2
Pancreatic Cancer	2
Hepatocellular Carcinoma (HCC)	2
Neoplasms	2
Esophageal Squamous Cell Carcinoma	2
Non-Small Cell Lung Cancer	2
Nasopharyngeal Carcinoma	2
Nasopharyngeal Cancer	2
Stage IB Lung Non-Small Cell Carcinoma AJCC v7	2
Stage II Lung Non-Small Cell Cancer AJCC v7	2
Advanced Malignant Solid Neoplasm	2
Stage IV Nasopharyngeal Carcinoma AJCC v8	2
Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8	2
Advanced Esophageal Adenocarcinoma	2
Advanced Gastric Adenocarcinoma	2
Advanced Gastroesophageal Junction Adenocarcinoma	2
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8	2
Epithelial Ovarian Cancer	1
Primary Peritoneal	1
Newly Diagnosed	1
Unresectable Renal Cell Carcinoma	1
Carcinoma, Non-Small-Cell Lung	1
Breast Cancer	1
Muscle-invasive Urothelial Carcinoma	1
Solid Tumors	1
Liver Cancer	1
Unresectable or Metastatic Hepatocellular Carcinoma	1
Child-Pugh A Hepatocellular Carcinoma	1
Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound	1
Non-Small Cell Lung Cancer (NSCLC)	1
Microsatellite Instability-High (MSI-H)	1
Non-melanoma Skin Cancer (NMSC)	1
Cutaneous Melanoma	1
High-risk Muscle Invasive Urothelial Carcinoma	1
Advanced Solid Tumor Historically Known for High EphA2 Expression	1
Urothelial Cancer	1
Unresectable Pleural Mesothelioma	1
Melanoma (Skin Cancer)	1
Skin Cancer	1
Non-Clear Cell Renal Cell Carcinoma	1
Renal Cell Carcinoma (RCC)	1
Metastatic Castration-Resistant Prostate Cancer (mCRPC)	1
Melanoma, Cutaneous Malignant	1
Mucosal Melanoma	1
ccRCC	1
RCC	1
Advanced Malignant Tumors	1
Diffuse Astrocytoma, IDH-Mutant	1
Glioblastoma, IDH-wildtype	1
Cervical Cancer	1
Classical Hodgkin Lymphoma	1
Hodgkin Disease Refractory	1
Hodgkin Disease Recurrent	1
Advanced Solid Tumor	1
Metastasis	1
Clear Cell Renal Cell Carcinoma (ccRCC)	1
Metastatic Non-Squamous Non-Small Cell Lung Cancer	1
Adult Solid Tumor	1
Gastroesophageal-junction Cancer	1
Metastatic Cancer	1
Refractory Cancer	1
Recurrent Cancer	1
Solid Tumor, Adult	1
Radiotherapy	1
Immunotherapy	1
Microsatellite Instability-High Solid Malignant Tumour	1
Metastasis From Malignant Tumor of Liver	1
Locally Advanced Solid Tumor	1
Carcinoma, Squamous	1
Antineoplastic Agents	1
Malignant Ascites	1
Recurrent Hepatocellular Cancer	1
Esophageal and/or Cardia Cancer	1
Malignant Melanoma Stage II	1
Leptomeningeal Disease	1
Nasopharyngeal Neoplasms	1
Nasopharynx Cancer	1
CNS Tumor	1
Localized Oesogastric Adenocarcimona	1
MSI and or dMMR	1
Metastatic Kidney Cancer	1
Metastatic Kidney Carcinoma	1
Metastatic Colorectal Cancer	1
Pediatric Cancer	1
Renal Cell Cancer	1
Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma	1
Gastric Adenocarcinoma	1
Esophagus Adenocarcinoma	1
Gastroesophageal Junction Adenocarcinoma	1
NSCLC	1
Pancoast Tumor	1
Adjuvant Chemotherapy	1
Cancer, Lung	1
Cancer of Lung	1
Mesothelioma	1
Urologic Neoplasms	1
Urogenital Neoplasms	1
Neoplasms by Site	1
Malignant Melanoma Stage III	1
Tumors	1
Neoplasm	1
Neoplasia	1
Cancer of Rectum	1
Malignant Melanoma	1
Colorectal Adenocarcinoma	1
Mucinous Adenocarcinoma	1
Signet Ring Cell Adenocarcinoma	1
Esophageal Cancer	1
Metastatic Malignant Neoplasm in the Bone	1
Metastatic Malignant Neoplasm in the Lymph Nodes	1
Metastatic Malignant Neoplasm in the Soft Tissue	1
Melanoma Stage Iv	1
Stage IIA Lung Cancer AJCC v8	1
Stage IIB Lung Cancer AJCC v8	1
Advanced Lymphoma	1
Bladder Carcinoma	1
Breast Carcinoma	1
Anal Basaloid Carcinoma	1
Anal Canal Cloacogenic Carcinoma	1
Anal Margin Squamous Cell Carcinoma	1
Stage IIB Anal Cancer AJCC v8	1
Stage II Nasopharyngeal Carcinoma AJCC v8	1
Stage III Nasopharyngeal Carcinoma AJCC v8	1
Anal Melanoma	1
Bladder Melanoma	1
Cervical Melanoma	1
Esophageal Melanoma	1
Metastatic Malignant Solid Neoplasm	1
Unresectable Malignant Solid Neoplasm	1
Acute Myeloid Leukemia	1
Down Syndrome	1
Recurrent B Acute Lymphoblastic Leukemia	1
Complete Surgical Resection	1
Circulating Tumor DNA	1
Metastatic Nasopharyngeal Carcinoma	1
Recurrent Nasopharyngeal Carcinoma	1
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8	1
Advanced Hepatocellular Carcinoma	1
Stage III Hepatocellular Carcinoma AJCC v8	1
Stage IV Hepatocellular Carcinoma AJCC v8	1
Sarcomatoid Renal Cell Carcinoma	1
Stage II Renal Cell Cancer AJCC v7	1
Stage III Renal Cell Cancer AJCC v7	1
Ann Arbor Stage III Hodgkin Lymphoma	1
Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma	1
Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma	1
Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma	1
Anal Canal Squamous Cell Carcinoma	1
Metastatic Anal Canal Carcinoma	1
Stage IV Anal Cancer AJCC v8	1
Primary Mediastinal Large B-Cell Lymphoma	1
Muscle Invasive Bladder Urothelial Carcinoma	1
Muscle Invasive Renal Pelvis Urothelial Carcinoma	1
Muscle Invasive Ureter Urothelial Carcinoma	1
Muscle Invasive Urethral Urothelial Carcinoma	1
Recurrent Squamous Cell Lung Carcinoma	1
Stage IV Squamous Cell Lung Carcinoma AJCC v7	1
Locally Advanced Extraskeletal Myxoid Chondrosarcoma	1
Locally Advanced Leiomyosarcoma	1
Locally Advanced Liposarcoma	1
Locally Advanced Undifferentiated Pleomorphic Sarcoma	1
Metastatic Large Cell Neuroendocrine Carcinoma	1
Metastatic Neuroendocrine Carcinoma	1
Metastatic Neuroendocrine Neoplasm	1
Metastatic Small Cell Neuroendocrine Carcinoma	1
Advanced Endometrial Carcinoma	1
Metastatic Endometrial Carcinoma	1
Recurrent Endometrial Carcinoma	1
Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8	1
Pancreatic Adenocarcinoma	1
Stage II Pancreatic Cancer AJCC v8	1
Stage III Pancreatic Cancer AJCC v8	1
Stage IV Pancreatic Cancer AJCC v8	1
Autoimmune Disease	1
Crohn Disease	1
Dermatomyositis	1
Hematopoietic and Lymphoid Cell Neoplasm	1
Basaloid Squamous Cell Carcinoma	1
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8	1
Oropharyngeal Squamous Cell Carcinoma	1
Uterine Cervical Neoplasms	1
Renal Cancer Metastatic	1
Clinical Stage III Esophageal Adenocarcinoma AJCC v8	1
Stage IIIA Lung Non-Small Cell Cancer AJCC v7	1
Cervical Adenocarcinoma	1
Cervical Adenosquamous Carcinoma	1
Recurrent Cervical Carcinoma	1
Stage IV Cervical Cancer AJCC v6 and v7	1
Metastatic Lung Non-Squamous Non-Small Cell Carcinoma	1
Recurrent Lung Non-Squamous Non-Small Cell Carcinoma	1
Stage IV Lung Cancer AJCC v8	1
Endometrial Adenocarcinoma	1
Endometrial Clear Cell Adenocarcinoma	1
Endometrial Dedifferentiated Carcinoma	1
Endometrial Endometrioid Adenocarcinoma	1
Acinar Cell Carcinoma	1
Adenoid Cystic Carcinoma	1
Adrenal Cortical Carcinoma	1
Adrenal Gland Pheochromocytoma	1
Stage III Cutaneous Melanoma AJCC v7	1
Stage IV Cutaneous Melanoma AJCC v6 and v7	1
Recurrent Classic Hodgkin Lymphoma	1
Refractory Classic Hodgkin Lymphoma	1
Melanoma of Unknown Primary	1
Clinical Stage II Esophageal Adenocarcinoma AJCC v8	1
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8	1
Recurrent Melanoma	1
Richter's Transformation	1
Endometrial Neoplasms	1
Endometrial Cancer	1
Hepato Cellular Carcinoma (HCC)	1
Immune Checkpoint Inhibitor	1
Neoadjuvant Therapy	1
Hepatocellular Cancer	1
Colorectal Carcinoma	1
HIV I Infection	1
Glioblastoma Multiforme	1
Follicular Lymphoma Stage II	1
Follicular Lymphoma Stage III	1
Follicular Lymphoma Stage IV	1
Glioblastoma	1
Malignant Glioma	1
Recurrent Glioblastoma	1
Recurrent Malignant Glioma	1
Melanoma Brain Metastases	1
Brain Metastases	1
Follicular Lymphoma	1
Advanced Biliary Tract Cancer	1
Neuroendocrine Tumors	1
Female Reproductive System Neoplasm	1
MSI-H Solid Malignant Tumor	1
Papillary Renal Cell Carcinoma	1
Unclassified Renal Cell Carcinoma	1
Translocation Renal Cell Carcinoma	1
Chromophobe Renal Cell Carcinoma	1
Renal Cancer	1
Genitourinary Cancer	1
Adrenocortical Carcinoma	1
Non-urothelial Bladder	1
Non-urothelial Upper Tract	1
Prostate Cancer	1
Metastatic Pancreatic Cancer	1
Rectal Cancer	1
Bladder Adenocarcinoma	1
Bladder Clear Cell Adenocarcinoma	1
Bladder Mixed Adenocarcinoma	1
Bladder Neuroendocrine Carcinoma	1
Advanced Glioblastoma	1
Metastatic Melanoma in the Central Nervous System	1
MGMT-Unmethylated Glioblastoma	1
Ann Arbor Stage I Hodgkin Lymphoma	1
Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma	1
Ann Arbor Stage I Nodular Sclerosis Classic Hodgkin Lymphoma	1
Ann Arbor Stage IA Hodgkin Lymphoma	1
Peritoneal Cancer	1
Metastatic Microsatellite Stable Colorectal Cancer	1
TFE3-Rearranged Renal Cell Carcinoma	1
Metastatic Colon Adenocarcinoma	1
Metastatic Rectal Adenocarcinoma	1
Stage III Colon Cancer AJCC v8	1
Stage III Rectal Cancer AJCC v8	1

By country register

Register	Trials	Recruiting
Clinical trials in USA	45	21
Clinical trials in Canada	41	17
Clinical trials in Spain	36	13
Clinical trials in Australia	35	16
Clinical trials in Israel	35	12
Clinical trials in Mexico	31	9
Clinical trials in France	31	15
Clinical trials in Germany	26	13
Clinical trials in Italy	25	10
Clinical trials in UK	23	10
Clinical trials in Netherlands	21	8
Clinical trials in Poland	17	7
Clinical trials in China	15	6
Clinical trials in South Korea	14	4
Clinical trials in Taiwan	14	3
Clinical trials in Brazil	13	6
Clinical trials in Belgium	12	2
Clinical trials in Czechia	11	3
Clinical trials in Japan	11	5
Clinical trials in Norway	11	2
Clinical trials in Denmark	10	4
Clinical trials in Egypt	10	1
Clinical trials in Turkey	8	3
Clinical trials in Singapore	8	3
Clinical trials in Austria	8	4
Clinical trials in Switzerland	7	4
Clinical trials in Sweden	6	2
Clinical trials in Portugal	6	3
Clinical trials in Ireland	5	2
Clinical trials in India	1	1

A trial with sites in more than one country appears in each of those registers.

Related compounds

Questions about Opdivo trials

How many clinical trials are testing Opdivo?

152 current trials in our USA, Canada, Spain, Australia, Israel, Mexico, France, Germany, Italy, UK, Netherlands, Poland, China, South Korea, Taiwan, Brazil, Belgium, Czechia, Japan, Norway, Denmark, Egypt, Turkey, Singapore, Austria, Switzerland, Sweden, Portugal, Ireland and India registers name Opdivo as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.

Are Opdivo trials recruiting patients?

Yes. 61 of the 152 trials are recruiting: 21 with sites in USA, 17 with sites in Canada, 13 with sites in Spain, 16 with sites in Australia, 12 with sites in Israel, 9 with sites in Mexico, 15 with sites in France, 13 with sites in Germany, 10 with sites in Italy, 10 with sites in UK, 8 with sites in Netherlands, 7 with sites in Poland, 6 with sites in China, 4 with sites in South Korea, 3 with sites in Taiwan, 6 with sites in Brazil, 2 with sites in Belgium, 3 with sites in Czechia, 5 with sites in Japan, 2 with sites in Norway, 4 with sites in Denmark, 1 with sites in Egypt, 3 with sites in Turkey, 3 with sites in Singapore, 4 with sites in Austria, 4 with sites in Switzerland, 2 with sites in Sweden, 3 with sites in Portugal, 2 with sites in Ireland and 1 with sites in India. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Opdivo clinical trials?

National Cancer Institute (NCI) (35), Bristol-Myers Squibb (10), Replimune, Inc (4) and Ono Pharmaceutical Co., Ltd (4), among 78 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Are there Opdivo clinical trials in Ireland?

Yes. 5 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Opdivo works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Opdivo works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Opdivo (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.